ArticleEuropean radiology2022
A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism.
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Comparison of Diagnostic Performance Between Standard Susceptibility Map-Weighted Imaging and Susceptibility Map-Weighted Imaging Reconstructed From Clinical SWI and Neuromelanin MRI in Early Parkinson's Disease.Journal of magnetic resonance imaging : JMRI · 2026Article
- MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum.Journal of Parkinson's disease · 2026Article
- Deep learning-based susceptibility map-weighted imaging analysis of dorsal nigral hyperintensity as a surrogate for dopamine transporter positron emission tomography in patients with idiopathic rapid eye movement sleep behavior disorder.Frontiers in neurology · 2026Article
- Deep Learning-Based Algorithm for Automatic Quantification of Nigrosome-1 and Parkinsonism Classification Using Susceptibility Map-Weighted MRI.AJNR. American journal of neuroradiology · 2025Article
- Susceptibility map-weighted MRI can distinguish tremor-dominant Parkinson's disease from essential tremor.Scientific reports · 2025Article
- Economic value of AI-based MRI triage for Parkinson's disease: a cost-benefit study in South Korea and the United States.Frontiers in public health · 2025Article
- Comparative Performance of Susceptibility Map-Weighted MRI According to the Acquisition Planes in the Diagnosis of Neurodegenerative Parkinsonism.Korean journal of radiology · 2024Observational
- Classification of Parkinson's disease by deep learning on midbrain MRI.Frontiers in aging neuroscience · 2024Article
- Accurate measurement of magnetic resonance parkinsonism index by a fully automatic and deep learning quantification pipeline.European radiology · 2023Article
- Ultra-high-field 7T MRI in Parkinson's disease: ready for clinical use?-a narrative review.Quantitative imaging in medicine and surgery · 2023Review
- Dorsolateral Nigral Hyperintensity on 1.5 T Versus 3 T Susceptibility-Weighted Magnetic Resonance Imaging in Neurodegenerative Parkinsonism.Movement disorders clinical practice · 2023Article
- Quantitative iron-neuromelanin MRI associates with motor severity in Parkinson's disease and matches radiological disease classification.Frontiers in aging neuroscience · 2023Article
- Application value of multiparametric MRI for evaluating iron deposition in the substantia nigra in Parkinson's disease.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 12 institutions in 1 country.
Funding
Abstract
objectivesThis study aimed to compare susceptibility map-weighted imaging (SMwI) using various MRI machines (three vendors) with N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophe nyl)nortropane (
methodsWe prospectively recruited 257 subjects, including 157 patients with neurodegenerative parkinsonism, 54 patients with non-neurodegenerative parkinsonism, and 46 healthy subjects from 10 hospitals between November 2019 and October 2020. All participants underwent both SMwI and
resultsThe inter-observer agreement was 0.924 and 0.942 per SN and participant, respectively. The diagnostic sensitivity of SMwI was 97.9% and 99.4% per SN and participant, respectively; its specificity was 95.9% and 95.2%, respectively, and its accuracy was 97.1% and 97.7%, respectively. There was no significant difference between the results of SMwI and
conclusionsThis study demonstrated that the high diagnostic performance of SMwI was maintained in a multi-centre setting with various MRI scanners, suggesting the generalisability of SMwI for determining nigrostriatal degeneration in patients with parkinsonism. KEY POINTS: • Susceptibility map-weighted imaging helps clinicians to predict nigrostriatal degeneration. • The protocol for susceptibility map-weighted imaging can be standardised across MRI vendors. • Susceptibility map-weighted imaging showed diagnostic performance comparable to that of dopamine transporter PET in a multi-centre setting with various MRI scanners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.